Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00077753
Recruitment Status : Completed
First Posted : February 16, 2004
Last Update Posted : January 11, 2011
Information provided by:

Brief Summary:

Primary objective:

  • To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd

Secondary objectives:

  • To assess the reduction in mortality rate at the end of the double-blind treatment period, at 3 (90 ± 10 days) and at 6 (180 ± 10 days) months from the time of entry to the study, in patients on extended prophylaxis
  • To assess the incidence of VTE at 3 months (90 ± 10 days) from the time of randomization to the study
  • To evaluate the safety of extended enoxaparin VTE prophylaxis in acutely ill medical patients with prolonged immobilization. Safety evaluation includes:

    • Major and minor hemorrhage
    • Heparin induced thrombocytopenia
    • Serious adverse events
  • To assess differences in levels of health-care utilization and cost between patients receiving extended VTE prophylaxis versus those receiving placebo.

Condition or disease Intervention/treatment Phase
Venous Thromboembolism Drug: enoxaparin sodium Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 4726 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization
Study Start Date : February 2002
Actual Primary Completion Date : October 2006
Actual Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. During double blind treatment : Cumulative occurrence of VTE assessed by ultrasound for all patients at 28±4 days after randomization (or earlier if symptomatic VTE) and/or V/Q lung scan for symptomatic patients ; Major hemorrhagic complications.

Secondary Outcome Measures :
  1. Occurrence of VTE between Day 1 and Day 90±10, Mortality at the end of Double-Blind Treatment, at 3 and 6 months
  2. Minor plus major hemorrhagic complications during Double-Blind Treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Recent immobilization ≤ 3 days
  • Level 1 mobility patients who are ≥ 40 years of age with acute medical illness or acute exacerbation of chronic medical illness
  • Level 2 mobility patients who

    • are >75 yrs of age
    • are ≥ 40 years of age and have a history of VTE (deep venous thrombosis or pulmonary embolism)
    • are ≥ 40 years of age and have a baseline diagnosis of cancer (active cancer or history of cancer)

Anticipated decreased level of mobility of 5 ± 2 days with a level of activity 1 and 2 at the time of study entry and likely to continue at a lower than pre-morbid activity level after the initial 5 ± 2 day period. PATIENTS DO NOT HAVE TO BE HOSPITALIZED IN ORDER TO BE INCLUDED IN THE STUDY.(Definition of decreased level of mobility: _Level 1:bed rest or sedentary patients _Level 2:level 1 with bathroom privileges)

  • Presence of at least one of the following medical conditions:

    • Heart Failure, NYHA class III and IV

      • Class III : Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitationdyspnea, or anginal pain.
      • Class IV : Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
    • Acute respiratory insufficiency
    • Other acute medical conditions such as:

      • Acute ischemic stroke, any territory, with an appropriate neuroradiologic (head CT scan or brain MRI scan) providing results consistent with non hemorrhagic stroke
      • acute infection without septic shock
      • acute rheumatic disorders
      • active episode of inflammatory bowel disease
      • active cancer defined as history of histologically or cytologically confirmed cancer in patients who are not candidates for debulking or curative intent surgery at study entry
      • Any other acute medical illness or exacerbation of chronic medical illness resulting in clinically significant reduction in mobility as compared to premorbid level.

Exclusion criteria:

  • Women who are breastfeeding, pregnant or of childbearing age and not using medically acceptable effective contraception
  • Patients with any evidence of an active bleeding disorder
  • Contraindication to anticoagulation
  • Major surgery within the previous 3 months
  • Patients who have had spinal or epidural analgesia or lumbar puncture within the preceding 24 hours
  • Known hypersensitivity to heparin, or LMWH, or pork derived products
  • A documented previous episode of heparin-induced or LMWH induced thrombocytopenia and/or thrombosis (HIT, HAT, or HITTS)
  • Patients who have taken part in another clinical trial within the previous thirty days
  • Patients with a persistent renal failure. The patient's creatinine level must be less than the creatinine level per gender/age/weight. This will replace the calculated creatinine clearance
  • Known or suspected severe anemia of unexplained cause considered clinically relevant by investigator
  • Patients with prosthetic heart valves
  • Patients with known cerebral metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00077753

Layout table for location information
United States, New Jersey
Bridgewater, New Jersey, United States
Buenos Aires, Argentina
North Ryde, Australia
Vienna, Austria
Brussels, Belgium
Sao Paulo, Brazil
Laval, Canada
Bogota, Colombia
Paris, France
Berlin, Germany
Mumbai, India
Natanya, Israel
Milan, Italy
Mexico, Mexico
Warsaw, Poland
Russian Federation
Moscow, Russian Federation
South Africa
Johannesburg, South Africa
Barcelona, Spain
Megrine, Tunisia
United Kingdom
Guildford, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Study Director: Luc Sagnard Sanofi

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00077753    
Other Study ID Numbers: XRP4563C_3501
First Posted: February 16, 2004    Key Record Dates
Last Update Posted: January 11, 2011
Last Verified: January 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases